Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > hyperhidrosis treatment market
Get a free sample of Hyperhidrosis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hyperhidrosis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Global hyperhidrosis treatment industry was valued at USD 671.6 million in 2023 and is anticipated to register 5.3% CAGR between 2024 and 2032 due to the increasing prevalence of hyperhidrosis and growing awareness and diagnosis rates.
The axillary segment in the market held 44.8% revenue share in 2023 due to high prevalence of axillary hyperhidrosis and wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers.
North America hyperhidrosis treatment market size is expected to record 5% CAGR between 2024 and 2032 due to the presence of advanced healthcare infrastructure, technological advancements and ongoing research initiatives.
AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel, Inc., Eirion Therapeutics, Inc, Eli Lilly and Company, Intas Pharmaceuticals Ltd and Kaken Pharmaceutical Co., Ltd., among others.